AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Moscone Center West
747 Howard Street San Francisco, CA 94103, United States
San Francisco, California


   American Association for Cancer Research

   Upcoming Conferences at the Forefront of Cancer Research

   November 12-16, 2011

   AACR - NCI - EORTC International Conference on Molecular Targets and
   Cancer Therapeutics

   Chairpersons TBD San Francisco, CA

   Please visit http://www.aacr.org/meetingcalendar often for additional
   conferences and program updates.

Schedule of Presentations:

Saturday, November 12, 2011
13:30:00 Educational Session 1 | Treatment of Premalignant Conditions Scott M Lippman
13:40:00 Preventing multiple types of cancer through HPV vaccination Douglas R LOWY
13:50:00 Use of presurgical models to screen active agents for intraepithelial neoplasia Andrea Decensi
14:00:00 Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists Paul A. Bunn
14:10:00 Cancer interception and reverse migration Scott M Lippman
15:30:00 Educational Session 2 | Clinical Trial Paradigms in the Era of Novel Therapies James H. DOROSHOW
15:40:00 New paradigms for early-phase clinical trials James H. DOROSHOW
15:50:00 Phasing out phase III trials? How much evidence do we need if the target is clearly hit? J. Verweij
16:00:00 Development of clinical trials incorporating genomic signatures: Lessons learned Lisa M McShane
16:10:00 Clinical trial designs for targeted therapies John F. Crowley
17:30:00 Networking Reception
Sunday, November 13, 2011
08:00:00 Opening Remarks and Keynote Lectures
08:10:00 Overcoming barriers to new drug development William Hait
08:20:00 Genomic profiling for personalized medicine
10:30:00 Plenary Session 1 | Novel Clinical Paradigms in Personalized Medicine José Baselga
10:40:00 Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer José Baselga
10:50:00 Optimizing targeted treatment of EGFR mutant lung cancer William Pao
11:00:00 Predicting response and resistance to targeted anticancer therapeutics Levi A Garraway
11:10:00 Title to be announced
12:30:00 Poster Session A
14:30:00 Plenary Session 2 | Lessons from the BRAF-targeted Therapy of Melanoma Neal Rosen
14:40:00 Changing cell fate in cancer: Lessons from melanoma Leonard I. Zon
14:50:00 BRAF and RAS signaling in cancer | From biology to therapeutics Richard M Marais
15:00:00 BRAF and MEK inhibition in melanoma Tona M Gilmer
15:10:00 Title to be announced Neal Rosen
16:30:00 Proffered Paper Session 1
18:00:00 Poster Session A (continued)
Monday, November 14, 2011
08:00:00 Plenary Session 3 | Developing Novel Validated Preclinical Models
08:10:00 The genomics of cancer therapeutics sensitivity
08:20:00 Building more predictive in vitro and in vivo models to identify responder populations preclinically
08:30:00 Developing pancreatic cancer medicine David A Tuveson
08:50:00 Genetic and preclinical interrogation of genetically engineered mouse models of lung cancer
10:30:00 Plenary Session 4 | Mechanistic-based Immunotherapy Cornelis J.M. Melief
10:40:00 Sipuleucel-T and the active immunotherapy of prostate cancer David Urdal
10:50:00 Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm Axel Hoos
11:00:00 Engineering improved cancer vaccines Glenn Dranoff
11:10:00 Synthetic long peptide vaccines against established disease caused by high-risk human papillomavirus Cornelis J.M. Melief
12:30:00 Poster Session B
14:25:00 Concurrent Sessions 1-4
14:30:00 Concurrent Session 2 | Mechanism-based Targeted Combination Therapies William C Hahn
14:30:00 Concurrent Session 1 | Finding the Best New Cancer Targets Paul Workman
14:30:00 Concurrent Session 3 | Challenges in PI3K Inhibition Jean- -Charles Soria
14:30:00 Concurrent Session 4 | Pharmacogenomics and Pharmacogenetics
14:40:00 Concurrent Session 4 | Polymorphic transporters and oncology drug safety Alex Sparreboom
14:40:00 Concurrent Session 1 | Finding the best new cancer targets: Approaches and challenges Paul Workman
14:40:00 Concurrent Session 3 | Mechanistic basis for treatment combinations with PI3K inhibitors Carlos L. Arteaga
14:40:00 Concurrent Session 2 | Functional genomics to identify targets and resistance William C Hahn
14:50:00 Concurrent Session 2 | Dual inhibition of mTOR and IGFR pathways
14:50:00 Concurrent Session 4 | Interrogating the heritable genome to achieve the goal of personalized cancer therapeutics Federico Innocenti
14:50:00 Concurrent Session 3 | Clinical development strategies of PI3K inhibitors Mika Derynck
14:50:00 Concurrent Session 1 | canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation
15:00:00 Concurrent Session 3 | Title to be announced Patricia LoRusso
15:00:00 Concurrent Session 1 | Identification of high-value targets for oncology drug discovery: Cancer genetics, synthetic lethality, and beyond
15:00:00 Concurrent Session 4 | Somatic driver mutations as a guide for anticancer treatment in lung cancer Bruce E. Johnson
15:00:00 Concurrent Session 2 | Targeting epigenomic and apoptotic proteins and pathways to treat leukemia and lymphoma
15:10:00 Concurrent Session 3 | PI3K pathway inhibitors: How deep should we go? Josep Tabernero
15:10:00 Concurrent Session 2 | Mechanisms of resistance to receptor tyrosine kinase inhibitors revealed through functional genetic screens René Bernards
15:10:00 Concurrent Session 1 | Identifying druggable targets from alterations in the cancer genome Matthew Meyerson
15:10:00 Concurrent Session 4 | Pharmacogenetic findings translated into clinical predictive biomarkers
16:30:00 Proffered Paper Session 2
18:00:00 Poster Session B (continued)
Tuesday, November 15, 2011
08:00:00 Plenary Session 5 | The Epigenome as a Therapeutic Target
08:10:00 MMSET | A pathogenic factor and therapeutic target in multiple myeloma Jonathan D Licht
08:20:00 Novel agents for epigenetic therapy Jean-Pierre Issa
08:30:00 Molecular basis and novel options for alternative epigenetic treatments against cancer
09:10:00 Targeting histone methyltransferases in tumor-sustaining cells Robert Brown
10:30:00 Plenary Session 6 | Targeting Tumor Stroma Interaction Nadia Harbeck
10:40:00 Impact of breast tumor microenvironment on treatment efficacy FABRICE ANDRE
10:50:00 Premetastatic niche | Opportunity for early intervention? David C Lyden
11:00:00 Urokinase plasminogen activator system | A multifunctional drug target Nadia Harbeck
11:10:00 Targeting the tumor ecosystem | Translating the molecular biology of chemokine interactions to the clinic Kenneth J Pienta
12:30:00 Poster Session C
14:25:00 Concurrent Sessions 5-8
14:30:00 Concurrent Session 5 | Targeting DNA Damage Response Beverly A Teicher
14:30:00 Concurrent Session 6 | Inhibition of Stem Cell Signaling Daniel Von Hoff
14:30:00 Concurrent Session 7 | Challenges in Genomic-based Characterization of Tumors Lynda Chin
14:30:00 Concurrent Session 8 | Advances in Targeted Hormonal Therapies Johann S. de Bono
14:40:00 Concurrent Session 5 | Mdm2 regulates DNA repair and chromosome stability
14:40:00 Concurrent Session 8 | Targeting the androgen receptor in castration-resistant prostate cancer Donald J Tindall
14:40:00 Concurrent Session 6 | Low dose azacytidine and epigenetic regulation of self renewal
14:40:00 Concurrent Session 7 | Accessing and using data from the International Cancer Genome Consortium (ICGC) to get insights into cancer genomes
14:50:00 Concurrent Session 5 | Targeting the Fanconi anemia/BRCA pathway in cancer therapy
14:50:00 Concurrent Session 8 | Androgens, biomarkers, and abiraterone Johann S. de Bono
14:50:00 Concurrent Session 7 | Target discovery with Oncomine: Discovering new targets and positioning old targets by integrative analysis of 10,000’s of tumor genomes and transcriptomes Daniel R. Rhodes
14:50:00 Concurrent Session 6 | The cancer stem cell niche Joan Seoane
15:00:00 Concurrent Session 6 | Regulation of breast cancer stem cells by cytokine networks Max S Wicha
15:00:00 Concurrent Session 7 | Title to be announced Lynda Chin
15:00:00 Concurrent Session 5 | Targeting molecular chaperones to induce telomere dysfunction
15:00:00 Concurrent Session 8 | Neoadjuvant androgen deprivation therapy for high-risk prostate cancer
15:10:00 Concurrent Session 8 | A combinatorial approach to targeting androgen receptor signaling in prostate cancer Wayne Tilley
15:10:00 Concurrent Session 6 | The hedgehog signaling pathway in cancer William H. Matsui
15:10:00 Concurrent Session 5 | Opportunities for targeting homologous recombination in human cancers
15:10:00 Concurrent Session 7 | Title to be announced
16:30:00 Poster Session C (continued)
Wednesday, November 16, 2011
08:00:00 Plenary Session 7 | Rational Cancer Drug Development for Targeted Drugs: The Interface Between Industry, Academia, and Regulators Frank McCormick
08:10:00 Title to be announced
08:20:00 Title to be announced Richard B Gaynor
08:30:00 FDA role in smoothing the progress of targeted drug development A. J. Murgo
09:00:00 Panelists
10:30:00 Plenary Session 8 | Targeting Tumor Metabolism
10:40:00 Clinical achievements reached by interfering with the IGF1R–PI3K–PTEN–AKT–mTOR axis
10:50:00 HIF-1 and reprogramming of cancer cell metabolism: Opportunities for therapy
11:00:00 Is there a role for metformin in cancer therapeutics? Ana Gonzalez-Angulo
11:10:00 New ways to impact glutamine metabolism in cancer
12:30:00 Closing Remarks | Adjournment
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.